FDAnews
www.fdanews.com/articles/96257-biocryst-starts-phase-ii-trial-of-intravenous-peramivir

Biocryst Starts Phase II Trial of Intravenous Peramivir

July 24, 2007

BioCryst Pharmaceuticals announced the initiation of a Phase II clinical trial in hospitalized patients using an intravenous formulation of peramivir, the company’s lead influenza neuraminidase inhibitor.

The multicenter, randomized, double-blind study will compare the efficacy and safety of peramivir administered intravenously once daily for five days with oral oseltamivir administered twice daily for five days in adults who are hospitalized with acute influenza, the company said.

The study will enroll patients in the U.S., Canada, Hong Kong, Singapore, Australia, New Zealand and South Africa, according to the company.

BioCryst said it is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services, which awarded the company a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza.